stocks logo

SLP

Simulations Plus Inc
$
13.150
+0.03(0.229%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
13.220
Open
13.090
VWAP
13.09
Vol
87.07K
Mkt Cap
264.07M
Low
12.980
Amount
1.14M
EV/EBITDA(TTM)
17.36
Total Shares
19.98M
EV
238.64M
EV/OCF(TTM)
16.80
P/S(TTM)
3.34
Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. It operates through two segments: software and services. The Company’s business units include cheminformatics, physiologically based pharmacokinetics, clinical pharmacology and pharmacometrics, quantitative systems pharmacology, adaptive learning & insights and medical communications. The Company operates in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. It delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Its cutting-edge technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
22.01M
-1.9%
--
--
18.14M
-4.13%
--
--
16.47M
-11.93%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Simulations Plus, Inc. (SLP) for FY2025, with the revenue forecasts being adjusted by -13.47% over the past three months. During the same period, the stock price has changed by -62.96%.
Revenue Estimates for FY2025
Revise Downward
down Image
-13.47%
In Past 3 Month
Stock Price
Go Down
down Image
-62.96%
In Past 3 Month
5 Analyst Rating
up Image
158.56% Upside
Wall Street analysts forecast SLP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLP is 34.00 USD with a low forecast of 28.00 USD and a high forecast of 40.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
up Image
158.56% Upside
Current: 13.150
sliders
Low
28.00
Averages
34.00
High
40.00
KeyBanc
Overweight -> Sector Weight
downgrade
2025-07-15
Reason
KeyBanc last night downgraded Simulations Plus to Sector Weight from Overweight without a price target. The company's fiscal Q3 results and forward outlook highlighted the ongoing challenged biopharma end market environment, the analyst tells investors in a research note. The firm believes the challenges will impact Simulations Plus "more sharply" given its customer concentration and biotech exposure. KeyBanc sees weaker customer demand continuing in the near-to-middle-term with no recovery in the biotech end market.
Stephens
Stephens
Overweight
downgrade
$28 -> $20
2025-07-15
Reason
Stephens lowered the firm's price target on Simulations Plus to $20 from $28 and keeps an Overweight rating on the shares. Simulations Plus reported slightly better than expected quarterly results, though adjusted EBITDA guidance was slightly lower than the firm modeled, the analyst says. The fourth quarter outlook represents conservatism rather than a further slide in fundamentals, and Stephens sees limited downside from here.
Craig-Hallum
Buy
downgrade
$36 -> $31
2025-07-15
Reason
Craig-Hallum lowered the firm's price target on Simulations Plus to $31 from $36 and keeps a Buy rating on the shares. The firm notes the company reported final Q3 results with revenues slightly ahead of the pre-release range and revenue guidance for FY25 reaffirmed. Craig-Hallum believes that the headwinds the company is facing will be relatively short-term in nature and given the recent regulatory guidance which calls for more use of AI/simulation in the discovery and development of pharmaceuticals, the firm thinks Simulations Plus will return to double-digit revenue growth and adjusted EBITDA margins of 30%-plus.
KeyBanc
Overweight -> Sector Weight
downgrade
2025-07-14
Reason
KeyBanc downgraded Simulations Plus to Sector Weight from Overweight.
BTIG
Buy
downgrade
$41 -> $25
2025-07-07
Reason
BTIG lowered the firm's price target on Simulations Plus to $25 from $41 and keeps a Buy rating on the shares following the firm's survey of biopharma manufacturers. R&D Services budgets will likely face the most risk and headwinds over the next 2 years, the analyst tells investors in a research note.
Craig-Hallum
Buy
downgrade
$45 -> $36
2025-06-13
Reason
Craig-Hallum lowered the firm's price target on Simulations Plus to $36 from $45 and keeps a Buy rating on the shares following the company's Q3 pre-release and lower FY25 guidance. The firm says that macro headwinds are affecting the company's services segment with customers delaying contract starts, slow walking signing new contracts or pushing out clinical trials. Craig-Hallum notes that although the changes to the business environment are unfortunate, Simulations Plus' software segment is holding up better and the business remains part of a growing market with the implementation of New Approach Methodologies, presenting an attractive opportunity to invest in the future of drug development.

Valuation Metrics

The current forward P/E ratio for Simulations Plus Inc (SLP.O) is 44.73, compared to its 5-year average forward P/E of 78.08. For a more detailed relative valuation and DCF analysis to assess Simulations Plus Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
78.08
Current PE
44.73
Overvalued PE
103.80
Undervalued PE
52.37

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
39.03
Current EV/EBITDA
11.80
Overvalued EV/EBITDA
57.43
Undervalued EV/EBITDA
20.64

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
15.07
Current PS
3.41
Overvalued PS
21.82
Undervalued PS
8.32

Financials

Annual
Quarterly
FY2025Q3
YoY :
+9.81%
20.36M
Total Revenue
FY2025Q3
YoY :
+59.31%
3.00M
Operating Profit
FY2025Q3
YoY :
-2245.90%
-67.32M
Net Income after Tax
FY2025Q3
YoY :
-2333.33%
-3.35
EPS - Diluted
FY2025Q3
YoY :
+49.29%
7.05M
Free Cash Flow
FY2025Q3
YoY :
-10.48%
64.00
Gross Profit Margin - %
FY2025Q3
YoY :
-13.80%
13.12
FCF Margin - %
FY2025Q3
YoY :
-2053.78%
-330.58
Net Margin - %
FY2025Q3
YoY :
-100.00%
N/A
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
1.6M
USD
3
3-6
Months
1.2M
USD
2
6-9
Months
1.8M
USD
5
0-12
Months
1.4M
USD
4
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
7.3K
Volume
1
6-9
Months
199.7K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

SLP News & Events

Events Timeline

2025-07-14 (ET)
2025-07-14
16:07:36
Simulations Plus cuts FY25 EPS view to 93c-$1.06 from $1.07-$1.20
select
2025-07-14
16:06:23
Simulations Plus reports Q3 adjusted EPS 45c, consensus 25c
select
2025-06-11 (ET)
2025-06-11
16:31:41
Simulations Plus cuts FY25 revenue view to $76M-$80M from $90M-$93M
select
Sign Up For More Events

News

7.0
07-23Globenewswire
INVESTOR ALERT: Investigation of Simulations Plus, Inc. (SLP) Announced by Holzer & Holzer, LLC
9.5
07-15Benzinga
Simulations Plus Sees Weaker Demand Persist, Outlook Softens
4.5
07-15Benzinga
Nasdaq Gains Over 100 Points; Wells Fargo Earnings Top Views
Sign Up For More News

FAQ

arrow icon

What is Simulations Plus Inc (SLP) stock price today?

The current price of SLP is 13.15 USD — it has increased 0.23 % in the last trading day.

arrow icon

What is Simulations Plus Inc (SLP)'s business?

arrow icon

What is the price predicton of SLP Stock?

arrow icon

What is Simulations Plus Inc (SLP)'s revenue for the last quarter?

arrow icon

What is Simulations Plus Inc (SLP)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Simulations Plus Inc (SLP)'s fundamentals?

arrow icon

How many employees does Simulations Plus Inc (SLP). have?

arrow icon

What is Simulations Plus Inc (SLP) market cap?